Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Syncona’s vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders. Its current investment portfolio consists of seven high quality companies in life science and a leading range of fund investments.
Syncona seeks to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. It is an established leader in gene therapy, cell therapy and advanced diagnostics, and focuses on delivering dramatic efficacy for patients in areas of high unmet need.
Syncona’s market leading funds portfolio seeks to generate superior returns by investing in long only and alternative investment funds. This represents a productively deployed evergreen funding base which enables Syncona to take a long term approach to investing in life sciences as it targets the best new opportunities and supports its existing portfolio companies to grow and succeed.
Syncona is aligned with two of the premium charitable funders in UK science, the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in the business. Syncona makes a donation of 0.3% of Net Asset Value to a range of charities each year.
Further information can be found at: Syncona
Cambridge Enterprise was established to aid the transfer of knowledge from the University of Cambridge through to commercialisation, achieved through intellectual property management and licensing, investment in University spin-outs and consultancy management and advice.
The Cambridge Enterprise Group comprises two legal entities of which Cambridge Enterprise Limited (formed on 1 December 2006) is a wholly owned subsidiary of the University of Cambridge. Cambridge Enterprise Limited has the responsibility of carrying out consultancy services, technology transfer functions and seed fund activities on behalf of the University.
Further information can be found at www.enterprise.cam.ac.uk
AMD is the leading cause of irreversible blindness in the elderly and today there is no effective treatment for the atrophic form of the diseaseView More +
Gyroscope Therapeutics Ltd is developing cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement systemView More +
Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.View More +